廣生堂(300436.SZ):水飛薊賓葡甲胺片正式參與到浙江臨牀一線抗擊疫情的戰“疫”中
格隆匯2月14日丨廣生堂(300436.SZ)公佈,近日,公司控股子公司江蘇中興藥業有限公司(“中興藥業”)產品水飛薊賓葡甲胺片被列入浙江省《臨時性納入掛網採購的新型冠狀病毒感染肺炎診療有關藥品目錄》(四),正式參與到浙江臨牀一線抗擊新型冠狀病毒肺炎疫情的戰“疫”中。
權威期刊《Lancet》(柳葉刀)研究文章顯示,2020年1月1-20日在武漢市金銀潭醫院確診的99個新型冠狀病毒肺炎病例中,有43例出現了不同程度的肝功能損傷,其中1例表現為嚴重肝損傷。水飛薊賓類藥物作為目前在世界範圍內被認可的一類天然植物保肝藥,是《藥物性肝損傷診治指南》明確的治療藥物性肝損傷的指南藥物,水飛薊賓葡甲胺片已被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2019年版)。
中興藥業作為公司旗下主要生產保肝護肝系列產品的企業,是國內較大的水飛薊系列產品的生產企業之一。為切實履行企業社會責任,中興藥業已向武漢疫情核心區主要醫院捐贈10000盒水飛薊賓葡甲胺片。同時,中興藥業已全面復工生產水飛薊賓葡甲胺片等藥品,確保產品供應,為更好地支持抗擊新型冠狀病毒肺炎疫情,為全國打贏這場疫情防控戰貢獻一份力量!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.